Research programme: extended-release therapeutics - Pacira

Drug Profile

Research programme: extended-release therapeutics - Pacira

Alternative Names: DepoMeloxicam; DepoMLX; DepoNSAID; DepoTranexamic Acid; DepoTXA

Latest Information Update: 12 Oct 2016

Price : $50

At a glance

  • Originator Pacira Pharmaceuticals
  • Class Cyclohexanecarboxylic acids; Nonsteroidal anti-inflammatories; Small molecules
  • Mechanism of Action Antifibrinolytic agents; Plasminogen activator inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Acute pain; Haematological disorders

Most Recent Events

  • 03 Oct 2016 Pacira Pharmaceuticals plans a phase II trial for Postoperative haemorrhage (in patients undergoing total knee arthroplasty) in USA (NCT02922582)
  • 24 Feb 2015 Pacira Pharmaceuticals plans a phase III trial for Acute pain and Haematological disorders (Pacira Pharmaceuticals 10-K, February 2015)
  • 31 Dec 2014 Preclinical trials in Haematological disorders in USA (Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top